Fairfield, CT -- (ReleaseWire) -- 03/07/2014 -- Competitive Technologies, Inc.(CTI), names Joel Bradus, former "Big Pharma" sales executive, U.S. division head of product sales. Mr. Bradus was appointed with the full responsibility of steering and expanding the Calmare products sales force in the United States.
Mr. Bradus spent 11 years at Schering-Plough including director level positions in institutional sales and business analysis. At Pfizer, he led quantitative analysis for the entire product line. Getting Dendrite started and profitable in this country, and 900% growth at Market Measures before being named Managing Director are just two of his accomplishments.
"Joel is the right man to grow sales," commented Competitive Technologies President & CEO Conrad Mir. "His expertise in pharmaceutical sales, product strategies and sales team building will help define CTI's product footprint in the pain management space."
Physicians interested in learning more about Calmare are encouraged to reach out to Mr. Bradus at email@example.com.
About Mr. Bradus
After a 30+ year career supporting the pharmaceutical industry, Mr. Bradus recently served as managing partner of The Concierge Inc., where he has helped grow a dozen businesses. His long record of accomplishments is split between the manufacturer and supplier sides of the industry. He spent 11 years at Schering including director level positions in institutional sales and business analysis. At Pfizer, he led quantitative analysis for the entire product line. Mr. Bradus was responsible for getting Dendrite started and profitable in this country with 900% growth at market measures before being named Managing Director are just two of Joel's accomplishments. He is frequent speaker at industry conferences and has served as adjunct faculty at the local college. Mr. Bradus is based in Spring Lake, NJ where he lives with his family.
About Competitive Technologies Inc.
Competitive Technologies Inc., (CTI),the pain mitigation company, develops and commercializes innovative wound and pain management products and technologies. CTI is the licensed distributor of the non-invasive Calmare® pain therapy medical device, which incorporates the biophysical "Scrambler Therapy"® technology developed to treat neuropathic and cancer-derived pain.
Certain statements contained in this press release are forward-looking statements that involve risks and uncertainties. The statements contained herein that are not purely historical are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements deal with the Company's current plans, intentions, beliefs and expectations and statements of future economic performance. Forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results in future periods to differ materially from what is currently anticipated. Factors that could cause or contribute to such differences include those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission. The Company cannot guarantee its future results, levels of activity, performance or achievements.